XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity and Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2024:

 

 

 

Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Term
(in years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Outstanding at December 31, 2023

 

 

8,715,529

 

 

$

4.70

 

 

 

 

 

 

 

Granted

 

 

2,274,990

 

 

$

9.20

 

 

 

 

 

 

 

Exercised

 

 

(51,540

)

 

$

3.86

 

 

 

 

 

 

 

Forfeited and cancelled

 

 

(123,025

)

 

$

6.21

 

 

 

 

 

 

 

Outstanding at March 31, 2024

 

 

10,815,954

 

 

$

5.63

 

 

 

8.1

 

 

$

89,201

 

Exercisable at March 31, 2024

 

 

4,521,533

 

 

$

4.42

 

 

 

6.9

 

 

$

43,542

 

Summary of Outstanding Shares of Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Share

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Options to purchase common stock

 

10,815,954

 

 

 

8,474,399

 

 Non-vested restricted stock units

 

695,246

 

 

 

485,942

 

Total

 

11,511,200

 

 

 

8,960,341

 

Summary of Fair Value of Stock Options Estimated Using Black-Scholes Merton Option Pricing Model Assumptions

The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions:

 

 

 

Three Months Ended
March 31,

 

 

2024

 

2023

Risk-free interest rate

 

3.82% - 4.19%

 

3.45%

Expected volatility

 

85.97% - 86.31%

 

87.68%

Expected term (in years)

 

6.08

 

6.08

Expected dividend yield

 

0%

 

0%

Summary of Total Stock-based Compensation Expense

The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations and comprehensive loss for the periods presented (in thousands):

 

 

Three Months Ended
March 31,

 

 

2024

 

 

2023

 

Research and development

$

2,145

 

 

$

1,475

 

General and administrative

 

2,813

 

 

 

2,139

 

Total stock-based compensation expense

$

4,958

 

 

$

3,614

 

Summary of Restricted Stock Unit Activity

The following table summarizes the restricted stock unit activity for the three months ended March 31, 2024:

 

 

Number of Shares

 

 

Weighted-
Average
Grant-Date
Fair Value

 

Outstanding at December 31, 2023

 

 

330,631

 

 

$

6.55

 

Granted

 

 

379,267

 

 

$

9.20

 

Vested

 

 

(3,245

)

 

$

7.01

 

Forfeited

 

 

(11,407

)

 

$

8.27

 

Outstanding at March 31, 2024

 

 

695,246

 

 

$

7.97